Abstract:BACKGROUND:Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of the insoluble drugs formulation. Paclitaxel (PTX) is a well-known BCS class IV drug with poor solubility and permeability. Also, many studies have proved that paclitaxel is a substrate of the membrane-bound drug efflux pump P-glycoprotein (P-gp), therefore it often shows limited efficacy against the resistant tumors and oral absorption or uptake. OBJECTIVE:To manufacture an enhanced-penetration PTX nanosuspension (PTX-Nanos), and evaluate the physicochemical property, pharmacokinetics and tissue distribution in vivo and cytotoxic effect in vitro. METHODS:PTX-Nanos were prepared by microprecipitation-high pressure homogenization, with a good biocompatibility amphiphilic block copolymer poly(L-phenylalanine)-b-poly(L-aspartic acid) (PPA-PAA) as stabilizer. RESULTS:The PTX-Nanos had a sustained-dissolution manner and could effectively reduce plasma peak concentration and extend plasma circulating time as compared to PTX injection, markedly passively targeting the MPS-related organs, such as liver and spleen. This unique property might enhance treatment of cancer in these tissues and reduce the side effects in other normal tissues. Moreover, the hybrid stabilizers could enhance penetration of PTX in PTX-Nanos to multidrug resistance cells. CONCLUSION:To sum up, our results showed that the optimal formula could improve the solubility of PTX and the stability of the product. The PTX-Nanos developed in this research would be a promising delivery platform in cancer treatment.

Recent progress in nanoformulations of cabazitaxel

Current development of cabazitaxel drug delivery systems

Cabazitaxel, a Novel Chemotherapeutic Alternative for Drug-Resistant Hepatocellular Carcinoma.

Current development in nanoformulations of docetaxel.

Current Development in Nanoformulations of Docetaxel

Emerging nanotaxanes for cancer therapy

Recent Progress of Paclitaxel Delivery Systems: Covalent and Noncovalent Approaches

Transforming a Toxic Drug into an Efficacious Nanomedicine Using a Lipoprodrug Strategy for the Treatment of Patient-Derived Melanoma Xenografts.

How Nanotechnology Can Enhance Docetaxel Therapy

Research Advances in Drug Delivery System of Cabazitaxel for Treatment of Patients with Prostate Cancer

Nanopaclitaxel therapy: an evidence based review on the battle for next-generation formulation challenges

Advances in nano-drug delivery systems for docetaxel

Exploration and Outlook of Recent Applications of Paclitaxel in Breast Cancer Treatment

Progress of Clinical Research on New Nano-Drug Delivery System of Paclitaxel

Research progress of paclitaxel drug delivery systems

Emerging Nanomedicines of Paclitaxel for Cancer Treatment

Akt inhibition improves the efficacy of cabazitaxel nanomedicine in preclinical taxane-resistant cancer models

Taxane anticancer agents: a patent perspective

Nanoscale drug delivery for taxanes based on the mechanism of multidrug resistance of cancer.

Advances in the formulations of non-injection administration of docetaxel.

Formulation, Pharmacokinetic Evaluation and Cytotoxicity of an Enhanced- penetration Paclitaxel Nanosuspension.